Merck Completes NovaCardia Buy
Merck & Co. announced Tuesday that it has completed its acquisition of San Diego-based NovaCardia. The deal, which was worth $366.4M in stock, adds NovaCardia's treatments for acute heart failure to Merck's pipeline. The deal was announced in July. NovaCardia was venture backed by Domain Associates, Forward Ventures, Montreux Equity Partners, Versant Ventures, Skyline Ventures, and InterWest Partners.
posted on Tuesday, September 11, 2007
Related companies:
Merck Capital Ventures
Related stories:
> NovaCardia Acquired By Merck
> NovaCardia Appoints CFO
> NovaCardia Files For IPO
> Merck Invests $90M In San Diego Research Group
> Ambrx in Collaboration Deal With Merck
socalTECH.com Home